Iraq's Healthcare Market Has One Buyer, and Selling Into It Is an Entirely Different Business

Update, 19 October 2026: the official dinar rate has changed

The 1,310 official rate quoted in this piece was in force when it was written on 11 August 2026. On 7 October 2026 Cabinet Resolution 544 of 2026 devalued the dinar: the CBI now sells to banks at 1,510, the Ministry of Finance buys at 1,500 and the bank retail ceiling is 1,520. Against the parallel rate of 1,632 the premium is now 8.1 percent, down from the mid teens cited below. The analysis is otherwise unchanged.

Key takeaways

• Healthcare and pharmaceuticals scores 40.0 on the GENQ Sector Vitality Radar, seventh of twelve tracked sectors and 4.9 points below the national composite of 44.9, with a delta of zero and no active positive or negative signals in the current window.
• Healthcare accounts for 3 of the 78 projects in the GENQ Project Tracker and $3.25 billion of $217.9 billion in tracked capital, or 1.5 percent, against a population of 47.02 million growing at 2.10 percent a year.
• Current health expenditure of 5.53 percent of GDP supports life expectancy at birth of 72.42 years, a combination that points to an allocation and delivery problem rather than an aggregate spending shortfall.
• GENQ has mapped 38 healthcare and pharmaceutical companies in Iraq, 25 Iraqi, 4 regional and 9 international, of which exactly one is listed on the Iraq Stock Exchange, so public equity is effectively absent as a funding channel for the sector.
• The parallel market premium on the dinar stands at 16.3 percent, official rate 1,310 and parallel 1,524 as of 11 August 2026, against a 127-day mean of 15.39 percent, and it falls directly on importers whose costs are dollar-denominated and whose receipts are not.
• Seven private hospitals are mapped against five public hospital complexes, a parallel private system forming in a country where the poverty headcount ratio at national poverty lines is 17.5 percent.

Kimadia Is Not a Participant in the Market, It Is the Market

The most useful fact about Iraqi healthcare commerce is organisational rather than clinical. Kimadia, the State Company for Marketing Drugs and Medical Appliances, sits under the Ministry of Health and is the channel through which the public system acquires medicines, consumables and much of its equipment. In GENQ's sector map it is the only entity classified as state procurement across 38 mapped companies. Everything else in the public half of the sector, from Baghdad Medical City to Basra Teaching Hospital to the Ghazi Al-Hariri Hospital for Surgical Specialties, sits downstream of it.

That produces a monopsony, and monopsony changes the commercial arithmetic in ways a market-sizing exercise will miss. In a competitive market a supplier prices against rivals and sells against demand. In a monopsony a supplier prices against a tender specification and sells against a registration file. The customer defines the product and decides the payment schedule. Sales capability matters far less than regulatory and tendering capability.

There is a corollary operators underuse. Because one entity aggregates most public demand, tender announcements and award notices are the highest-information public data series in the sector, revealing therapeutic priorities, volume assumptions, budget execution rhythm and, over time, which suppliers are being paid.

Iraq Is Not Underspending on Health in the Way the Headline Suggests

Current health expenditure of 5.53 percent of GDP is modest by upper-middle-income standards, and it is tempting to read it as the sector's central problem. The life expectancy series argues against that reading. Life expectancy at birth of 72.42 years is a respectable outcome, achieved alongside universal access to electricity and an adult literacy rate of 84.06 percent. Iraq is not buying poor population health outcomes at a low price. It is buying reasonable ones.

The honest statement is narrower and more useful: the binding constraint is allocation and delivery, not the aggregate envelope. GDP per capita of $5,410 means 5.53 percent of output is a small absolute per-head sum, so the system depends heavily on how efficiently that sum converts into care, and a population growing at 2.10 percent a year and 69.94 percent urban concentrates demand on urban tertiary facilities faster than the facility base expands.

For an operator, arguments framed around raising total health spending are unlikely to move procurement. Arguments framed around cost per treated patient, throughput, avoided referral abroad and reduced wastage speak to the question the system actually faces. That is where diagnostics, imaging and supply chain technology find their case, and why the three device and imaging names GENQ maps, GE HealthCare, Siemens Healthineers and Philips Healthcare, compete on service and uptime economics rather than unit price alone.

Three Projects and $3.25 Billion Is a Thin Public Pipeline

The GENQ Project Tracker records 78 projects with a combined announced value of $217.9 billion. Healthcare accounts for three of them and $3.25 billion, or 1.5 percent of tracked capital. Oil and gas alone carries $127.14 billion.

The pipeline is entirely public in funding type, with no private, FDI or multilateral healthcare project recorded, and it is concentrated in physical capacity rather than operating models, workforce or supply chain. One of the three is delivered by a Chinese contractor, consistent with the pattern in Iraqi education and power construction.

A thin pipeline is not thin demand. Hospital construction is the most visible and least frequent form of healthcare spending; recurrent procurement of medicines, consumables and maintenance is larger in aggregate and is not captured in a project tracker at all. Capital formation in Iraqi healthcare is small relative to hydrocarbons and transport, and suppliers should not build an Iraq strategy around greenfield hospital pipelines.

The Regional Manufacturers Are the Structurally Advantaged Group

GENQ's sector map records five domestic pharmaceutical manufacturers (Samarra Drug Industries, Nineveh Drug Industries, Al-Mansour Pharmaceutical Industries, Pioneer Company for Pharmaceutical Industries and Awamedica), six multinationals (Sanofi, Novartis, Pfizer, Novo Nordisk, AstraZeneca and Abbott) and four regional players (Hikma Pharmaceuticals, Julphar, Tabuk Pharmaceuticals and Dar Al Dawa). The regional group is the one to watch, and the reasons are structural rather than reputational.

Registration is the first. Arab regional manufacturers file dossiers in Arabic against Middle Eastern regulatory conventions and have done so in Iraq for decades. Registration is the gate through which every unit of public demand must pass, and incumbency at that gate compounds. Price point is the second: regional generics occupy the band between domestic production and originator pricing, precisely the band a tender optimising on cost per treatment course selects. Logistics is the third. Jordan, the UAE and Saudi Arabia supply Iraq overland or by short sea routes, with shorter lead times, lower cold chain risk and less letter of credit friction.

The multinationals hold the categories where substitution is hard: oncology, cardiology, and increasingly metabolic and endocrine treatment. They typically operate through registered scientific bureaux rather than direct distribution, which distances them from collection risk and from the dinar problem below, at the cost of margin and market intelligence.

A Sixteen Percent Currency Premium Is a Contract Design Problem

The official rate is 1,310 dinars to the dollar and the parallel rate is 1,524, a premium of 16.3 percent as of 11 August 2026, against a mean of 15.39 percent across 127 daily observations and a standard deviation of 2.03. GENQ's correlation engine describes this as an elevated but stable gap: chronic distortion rather than acute crisis.

For this sector the transmission is unusually direct. Active pharmaceutical ingredients, packaging, reagents, imaging tubes and spare parts are dollar-priced. Kimadia tenders and out-of-pocket patient payments are denominated in dinars. A supplier that wins at a dinar price and settles its own costs at anything other than the official rate absorbs the gap, and because tender and payment cycles are long, the exposure is a position held open for months rather than a single conversion event.

Three contracting mechanics follow. The currency of quotation and the applicable rate should be named explicitly in the bid, since an unstated assumption defaults to whichever rate the counterparty applies. The premium's volatility, a standard deviation of 2.03 around a mean of 15.39 percent, is small relative to its level, so the sensible hedge is a level adjustment priced into the bid rather than an attempt to time the rate. And payment timing dominates: a 16 percent premium on a receivable settled in 60 days is a different exposure from the same premium settled in 300 days.

A Private System Is Forming Alongside the Public One

Seven private hospitals against five public hospital complexes is a meaningful ratio in a register of 38. The private names cluster in the Kurdistan Region and in shrine-funded institutions: Faruk Medical City, Zheen International Hospital, Par Hospital, CMC Hospital, Bnar Private Hospital and Al-Rahibat, alongside Al-Kafeel Super Specialty Hospital and the Warith International Cancer Institute. Only one company in the entire sector is listed on the Iraq Stock Exchange, so this expansion is financed privately, by endowment or by religious foundation rather than through public equity.

The equity dimension is factual. Private hospital care in Iraq is funded predominantly out of pocket, in a country where the poverty headcount ratio at national poverty lines is 17.5 percent. That has two commercial consequences. Private capacity growth is bounded by household ability to pay rather than clinical demand, and will concentrate in higher-income urban catchments and in procedures where patients currently travel abroad. And any future health financing reform, insurance or otherwise, would change the addressable private market more than any construction programme would.

Demography Is Rewriting the Therapeutic Mix

The forward thesis for Iraqi healthcare is demographic. A population of 47.02 million growing at 2.10 percent, 69.94 percent urban, with life expectancy at 72.42 years, is a population moving through the epidemiological transition. The burden shifts from communicable and maternal conditions towards cardiovascular disease, diabetes, renal disease and cancer. That shift changes what the system buys.

Chronic disease demands continuous therapy rather than episodic treatment, which favours suppliers who can guarantee uninterrupted supply over those who can win a single tender. It raises demand for diagnostics, imaging and the service contracts that keep installed equipment running. It increases the value of oncology and metabolic portfolios, where the multinational names are positioned. And it lengthens the average patient relationship, the economic foundation on which private hospital groups build.

The five specialist centres in the map, including Ibn Al-Bitar for cardiac surgery, the Hiwa Cancer Hospital and Nanakali for blood diseases and cancer, show this transition is already visible in the institutional register rather than merely projected.

What Centralised Procurement Did Elsewhere

Iraq is not the first large market to run drug purchasing through a central agency. China's move to national volume-based procurement from 2018 consolidated demand for off-patent molecules into single national tenders. The result was steep price compression, rapid consolidation among domestic generic manufacturers, and a decisive shift of capital towards firms that could compete on manufacturing cost and quality certification at scale. Smaller producers without that cost base did not survive. Egypt's long experience with centralised public procurement points the same way: centralisation delivers price leverage, and it concentrates the supplier base.

The lesson for Iraq's five domestic manufacturers is not that centralisation will destroy them. It is that a monopsony rewards cost position and regulatory compliance above all else, and that local preference protects a producer only while the price gap against regional generics stays within tolerance. With inputs dollar-priced and the dinar carrying a 16.3 percent premium, that gap is not fully within domestic producers' control.

The Samarra Judgment Is Evidence, and the National Score Is Not a Thesis

In the current window, a Jordanian court ordered a Jordanian company to pay damages to the General Company for the Pharmaceutical Industry and Medical Supplies in Samarra following a contract dispute. It is the only healthcare item in GENQ's news signal set for the period, which itself says something about the sector's public information flow. It is evidence that an Iraqi state pharmaceutical entity pursued cross-border recourse through a foreign commercial court and obtained a favourable outcome, and enforceability is the quiet variable in every supply agreement with an Iraqi state counterparty.

It should not be over-extrapolated. One judgment in one jurisdiction does not establish a reliable enforcement environment, and the direction of recourse here is a state buyer recovering from a foreign supplier, not a supplier recovering from a state buyer. The latter remains the harder case and the one that sets commercial risk appetite. GENQ's regulatory risk reading of 60 on a 100-point scale, high but trending down, is the appropriate frame.

The Iraq Business Viability Index reads 28.2 as of 11 August 2026, classification critical, against a mean of 29.9 and a standard deviation of 1.36 over the observation window. That is a measurement of the operating environment, not of demand, and precision here matters more than tone.

Two IBVI dimensions bear most heavily on healthcare. Currency and liquidity carries the largest weight at 22 percent, for the reason already traced: a dollar-cost, dinar-revenue sector transmits the parallel premium straight to margin. Regulatory clarity, at 17 percent, is the second, because registration timelines, customs treatment of pharmaceutical and device consignments and licensing speed determine whether a product can be bid at all.

The decisive point is that these national readings do not predict sector performance. Across 52 observations, GENQ's correlation engine measures the relationship between national viability and sector vitality at r = 0.09. The two series move independently. An investment committee that screens Iraq on a country score and stops there will conclude the sector is uninvestable, when the data says the two scores answer different questions. Healthcare and pharmaceuticals at 40.0, with a delta of zero and no active signals, sits 4.9 points below the composite of 44.9 and level with energy and renewables: stable and structurally constrained, and the national score adds almost nothing to that.

What GENQ Is Watching

About this analysis. Figures are drawn from the GENQ data estate as at 11 August 2026, including the Iraq Business Viability Index, the Sector Vitality Radar, the GENQ Project Tracker and the GENQ Iraq Sector Map, alongside published World Bank indicators, which are latest available observations and not all of the same reference year. Index readings are point-in-time and revised as new data is acquired. Company and project counts reflect GENQ's mapped coverage rather than a complete national register. Comparative observations on centralised procurement elsewhere are analytical assessments, not GENQ measurements. GENQ Analytics, gen-q.ai.